The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Synthesis and Preclinical Evaluation of 11 C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain
Open accessAbstract
UNLABELLED: The synaptic vesicle glycoprotein 2A (SV2A) is found in secretory vesicles in neurons and endocrine cells. PET with a selective SV2A radiotracer will allow characterization of drugs that modulate SV2A (e.g., antiepileptic drugs) and potentially could be a biomarker of synaptic density (e.g., in neurodegenerative disorders). Here we describe the synthesis and characterization of the SV2A PET radiotracer (11)C-UCB-J ((R)-1-((3-((11)C-methyl-(11)C)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one) in nonhuman primates, including whole-body biodistribution. METHODS: (11)C-UCB-J was prepared by C-(11)C-methylation of the 3-pyridyl trifluoroborate precursor with (11)C-methyl iodide via the Suzuki-Miyaura cross-coupling method. Rhesus macaques underwent multiple scans including coinjection with unlabeled UCB-J (17, 50, and 150 μg/kg) or preblocking with the antiepileptic drug levetiracetam at 10 and 30 mg/kg. Scans were acquired for 2 h with arterial sampling and metabolite analysis to measure the input function. Regional volume of distribution (VT) was estimated using the 1-tissue-compartment model. Target occupancy was assessed using the occupancy plot; the dissociation constant (Kd) was determined by fitting self-blocking occupancies to a 1-site model, and the maximum number of receptor binding sites (Bmax) values were derived from baseline VT and from the estimated Kd and the nondisplaceable distribution volume (VND). RESULTS: (11)C-UCB-J was synthesized with greater than 98% purity. (11)C-UCB-J exhibited high free fraction (0.46 ± 0.02) and metabolized at a moderate rate (39% ± 5% and 24% ± 3% parent remaining at 30 and 90 min) in plasma. In the monkey brain, (11)C-UCB-J displayed high uptake and fast kinetics. VT was high (∼25-55 mL/cm(3)) in all gray matter regions, consistent with the ubiquitous expression of SV2A. Preblocking with 10 and 30 mg/kg of levetiracetam resulted in approximately 60% and 90% occupancy, respectively. Analysis of the self-blocking scans yielded a Kd estimate of 3.4 nM and Bmax of 125-350 nM, in good agreement with the in vitro inhibition constant (Ki) of 6.3 nM and regional Bmax in humans. Whole-body biodistribution revealed that the liver and the brain are the dose-limiting organs for males and females, respectively. CONCLUSION: (11)C-UCB-J exhibited excellent characteristics as an SV2A PET radiotracer in nonhuman primates. The radiotracer is currently undergoing first-in-human evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“new imaging tools have the potential to identify biomarkers of psychoplastogen efficacy”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [104]
Experimental — accuracy not yet measuredIn the citing paper
“Of these, [ 11 C]UCB-J possessed the most suitable pharmacokinetics, i.e., rapid and high brain uptake, reversible binding kinetics, and relatively low nonspecific binding in white matter”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [117]
In the citing paper
“Three of the SV2A ligands were radiolabeled as [ 11 C] UCB-A [112], [ 18 F]UCB-H [113-116], and [ 11 C]UCB-J [117], and all were evaluated in nonhuman primates (NHP).”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease
Rhinn, H., Fujita, R., Qiang, L., Cheng, R., Lee, J. H., & Abeliovich, A. (2013) · Nature · doi:10.1038/nature12415 · Cited by 151
RetractedThe synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Differential expression of synaptic vesicle protein 2 (SV2) isoforms
Bajjalieh, S., Frantz, G., Weimann, J., McConnell, S., & Scheller, R. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05223.1994 · Cited by 440
Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415 · cited 1×
“Mice deficient in SV2A develop seizures and die within 3 wk of birth (4).”
BackgroundStrategies to Improve Neuroreceptor Parameter Estimation by Linear Regression Analysis
Ichise, M., Toyama, H., Innis, R. B., & Carson, R. E. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/01.wcb.0000038000.34930.4e · Cited by 358
Self-citationFyn inhibition rescues established memory and synapse loss in Alzheimer mice
Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., Robinson, S. A., Gunther, E. C., van Dyck, C. H., Nygaard, H. B., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24394 · Cited by 314
Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited
Cunningham, V. J., Rabiner, E. A., Slifstein, M., Laruelle, M. A., & Gunn, R. N. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.190 · Cited by 270
Self-citationSV2, a Brain Synaptic Vesicle Protein Homologous to Bacterial Transporters
Bajjalieh, S. M., Peterson, K., Shinghal, R., & Scheller, R. H. (1992) · Science · doi:10.1126/science.1519064 · Cited by 256
Column-switching HPLC for the analysis of plasma in PET imaging studies
Hilton, J., Yokoi, F., Dannals, R. F., Ravert, H. T., Szabó, Z. R., & Wong, D. F. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00125-6 · Cited by 222
Robinson, J. L., Molina-Porcel, L., Corrada, M. M., Raible, K., Lee, E. B., Lee, V. M.-Y., Kawas, C. H., & Trojanowski, J. Q. (2014) · Brain · doi:10.1093/brain/awu190 · Cited by 157
Flagged first, then by citations
Research works printed but not linked: 2
- Lubberink M Estrada S Thibblin A . Pre-clinical evaluation and kinetic modelling of 11C-UCB-A as a PET tracer for synaptic vesicle protein 2A. Abstract presented at: The 10th International Symposium on Functional NeuroReceptor Mapping of the Living Brain; May 21–24, 2014, Amsterdam, The Netherlands.
- Estrada S Thibblin A Johansen P . Synthesis, biodistribution and radiation dosimetry of 11C-UCB-A, a novel PET tracer for synaptic vesicle protein 2A. Abstract presented at: The 10th International Symposium on Functional NeuroReceptor Mapping of the Living Brain; May 21–24, 2014; Amsterdam, The Netherlands.
Cited by
Sorted by citations
Items 101–200 of 297
Changes in synaptic density in the subacute phase after ischemic stroke: A 11 C-UCB-J PET/MR study
Michiels, L., Mertens, N., Thijs, L., Radwan, A., Sunaert, S. G., Vandenbulcke, M., Verheyden, G., Koole, M., Laere, K. V., & Lemmens, R. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211047759 · Cited by 31
PET Imaging in Animal Models of Alzheimer’s Disease
Chen, B., Marquez-Nostra, B. V., Belitzky, E., Toyonaga, T., Tong, J., Huang, Y. H., & Cai, Z. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.872509 · Cited by 27
Self-citationAndersen, K. B., Hansen, A. K., Schacht, A. C., Horsager, J., Gottrup, H., Klit, H., Danielsen, E. H., Poston, K. L., Pavese, N., Brooks, D. J., et al. (2023) · Movement Disorders · doi:10.1002/mds.29375 · Cited by 30
Leveraging ultra-high field (7T) MRI in psychiatric research
Calabro, F. J., Parr, A. C., Sydnor, V. J., Hetherington, H. P., Prasad, K. M. R., Ibrahim, T. S., Sarpal, D. K., Famalette, A., Verma, P., & Luna, B. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01980-6 · Cited by 29
Wang, R., Liu, H., Toyonaga, T., Shi, L., Wu, J., Onofrey, J. A., Tsai, Y., Naganawa, M., Ma, T., Liu, Y., et al. (2021) · Medical Physics · doi:10.1002/mp.15073 · Cited by 28
Self-citationHealthy brain aging assessed with [18F]FDG and [11C]UCB-J PET
Andersen, K. B., Hansen, A. K., Knudsen, K., Schacht, A. C., Damholdt, M. F., Brooks, D. J., & Borghammer, P. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.06.007 · Cited by 25
Xiong, M., Roshanbin, S., Rokka, J., Schlein, E., Ingelsson, M., Sehlin, D., Eriksson, J., & Syvänen, S. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118302 · Cited by 24
Navacerrada, M. E. S., Bahri, M. A., Becker, G., Seret, A., Germonpré, C., Lemaire, C. F., Giacomelli, F., Miévis, F., Luxen, A., Salmon, É., et al. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01488-7 · Cited by 23
Bini, J., Naganawa, M., Nabulsi, N., Huang, Y. H., Ropchan, J. R., Lim, K., Najafzadeh, S., Herold, K. C., Cline, G. W., & Carson, R. E. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.197285 · Cited by 23
Self-citationZhuo, C., Tian, H., Li, G., Chen, M., Jiang, D., Lin, X., Xu, Y. J., & Wang, W. (2019) · Brain and Behavior · doi:10.1002/brb3.1423 · Cited by 26
Raval, N. R., Gudmundsen, F., Juhl, M., Andersen, I. V., Speth, N., Videbæk, A., Petersen, I. N., Mikkelsen, J. D., Fisher, P. M., Herth, M. M., et al. (2021) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2021.715811 · Cited by 22
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 27
Astrocyte Signature in Alzheimer’s Disease Continuum through a Multi-PET Tracer Imaging Perspective
Fontana, I. C., Scarpa, M., Malarte, M., Rocha, F. M., Ausellé‐Bosch, S., Blūma, M., Bucci, M., Chiotis, K., Kumar, A., & Nordberg, A. K. (2023) · Cells · doi:10.3390/cells12111469 · Cited by 22
Nabulsi, N., Holden, D., Zheng, M., Bois, F., Lin, S.-F., Najafzadeh, S., Gao, H., Ropchan, J. R., Lara‐Jaime, T., Labaree, D. C., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.222034 · Cited by 21
Self-citationSephton, S. M., Miklovicz, T., Russell, J. J., Doke, A. K., Li, L., Boros, I., & Aigbirhio, F. I. (2020) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3828 · Cited by 21
Toyonaga, T., Fesharaki-Zadeh, A., Strittmatter, S. M., Carson, R. E., & Cai, Z. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.787404 · Cited by 20
Self-citationBini, J., Holden, D., Fontaine, K. M., Mulnix, T., Lu, Y., Matuskey, D., Ropchan, J. R., Nabulsi, N., Huang, Y. H., & Carson, R. E. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00670-w · Cited by 19
Self-citationLi, J., Huang, Q., Qi, N., He, K., Li, S., Huang, L., Pan, F., Ren, S., Hua, F., Huang, Y. H., et al. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241230733 · Cited by 19
Self-citationRecent Developments in Molecular Brain Imaging of Neuropsychiatric Disorders
Slifstein, M., & Abi‐Dargham, A. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.002 · Cited by 22
Imaging Synaptic Density: A Different Look at Neurologic Diseases
Rabiner, E. A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198317 · Cited by 20
Neurological update: neuroimaging in dementia
Rittman, T. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10040-0 · Cited by 23
Glorie, D., Verhaeghe, J. A. J., Miranda, A., Lombaerde, S. D., Stroobants, S. G., & Staelens, S. G. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00721-2 · Cited by 20
Fang, X. T., Volpi, T., Holmes, S. E., Esterlis, I., Carson, R. E., & Worhunsky, P. D. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1124254 · Cited by 18
Self-citationUse of carbon-11 labelled tool compounds in support of drug development
Boscutti, G., Huiban, M., & Passchier, J. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.11.009 · Cited by 19
Novel Tracers and Radionuclides in PET Imaging
Mason, C. A., Gimblet, G. R., Lapi, S. E., & Lewis, J. S. (2021) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2021.05.012 · Cited by 19
Analysis of Differential Expression of Synaptic Vesicle Protein 2A in the Adult Rat Brain
Mendoza-Torreblanca, J. G., García-Cruz, M. E., Sánchez-Cruz, I., Gomez-Gonzalez, B., Juárez-Méndez, S., & Gómez-Lira, G. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.09.004 · Cited by 18
Emsell, L., Laroy, M., Cauwenberge, M. G. A. V., Casteele, T. V., Vansteelandt, K., Laere, K. V., Sunaert, S. G., den Stock, J. V., Bouckaert, F., & Vandenbulcke, M. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03063-y · Cited by 17
PET imaging of synaptic density in Parkinsonian disorders
Martin, S. L., Uribe, C., & Strafella, A. P. (2023) · Journal of Neuroscience Research · doi:10.1002/jnr.25253 · Cited by 19
PET Imaging of Synaptic Vesicle Protein 2A
Finnema, S. J., Li, S., Cai, Z., Naganawa, M., Chen, M.-K., Matuskey, D., Nabulsi, N., Esterlis, I., Holmes, S. E., Radhakrishnan, R., et al. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_29 · Cited by 17
Self-citationLopresti, B. J., Royse, S. K., Mathis, C. A., Tollefson, S., & Narendran, R. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15615 · Cited by 16
Guan, B., Zhou, N., Wu, C., Li, S., Chen, Y., Debnath, S., Hofstad, M. E., Ma, S., Raj, G. V., He, D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313085 · Cited by 15
Self-citationJuengling, F. D., Wuest, F. R., Kalra, S., Agosta, F., Schirrmacher, R., Thiel, A., Thaiss, W. M., Müller, H., & Kassubek, J. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.890425 · Cited by 16
Longitudinal Synaptic Density PET with 11C‐UCB‐J 6 Months After Ischemic Stroke
Michiels, L., Thijs, L., Mertens, N., Coremans, M., Vandenbulcke, M., Verheyden, G., Koole, M. J. B., Laere, K. V., & Lemmens, R. (2022) · Annals of Neurology · doi:10.1002/ana.26593 · Cited by 13
Jensen, K. H. R., Dam, V. H., Ganz, M., Fisher, P. M., Ip, C.-T., Sankar, A., Marstrand-Joergensen, M. R., Ozenne, B., Osler, M., Penninx, B. W. J. H., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04618-x · Cited by 16
An In Vivo High-Resolution Human Brain Atlas of Synaptic Density
Johansen, A., Beliveau, V., Colliander, E., Raval, N. R., Dam, V. H., Gillings, N., Aznar, S., Svarer, C., Plavén‐Sigray, P., & Knudsen, G. M. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.1750-23.2024 · Cited by 14
Preclinical PET Studies of [11C]UCB-J Binding in Minipig Brain
Thomsen, M. B., Schacht, A. C., Alstrup, A. K. O., Jacobsen, J., Lillethorup, T. P., Bærentzen, S. L., Noer, O., Orłowski, D., Elfving, B., Müller, H. K., et al. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01506-8 · Cited by 14
Asch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
Self-citationStructures of synaptic vesicle protein 2A and 2B bound to anticonvulsants
Mittal, A., Martin, M. F., Levin, E. J., Adams, C., Yang, M., Provins, L., Hall, A., Procter, M. J., Ledecq, M., Hillisch, A., et al. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01335-1 · Cited by 15
SV2A PET shows hippocampal synaptic loss in cognitively unimpaired APOE ε4/ε4 homozygotes
Snellman, A., Tuisku, J., Koivumäki, M., Wahlroos, S., Aarnio, R., Rajander, J., Karrasch, M., Ekblad, L. L., & Rinne, J. O. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14327 · Cited by 16
Foster, C., Steventon, J. J., Helme, D., Tomassini, V., & Wise, R. G. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00360 · Cited by 16
In vivo study sheds new light on the dendritic spine pathology hypothesis of schizophrenia
Li, W., Lv, L., & Luo, X. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01449-2 · Cited by 14
Synaptic density in aging mice measured by [18F]SynVesT-1 PET
Xiong, M., Roshanbin, S., Sehlin, D., Hansen, H. D., Knudsen, G. M., Rokka, J., Eriksson, J., & Syvänen, S. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.120230 · Cited by 12
Improved synthesis of SV2A targeting radiotracer [11C]UCB-J
Rokka, J., Schlein, E., & Eriksson, J. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0080-5 · Cited by 14
Botermans, W., Koole, M. J. B., Laere, K. V., Savidge, J. R., Kemp, J. A., Sunaert, S. G., Duffy, M. M., Ramael, S., Cesura, A. M., D’Ostilio, K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066447 · Cited by 13
AD molecular: Molecular imaging of Alzheimer's disease: PET imaging of neurotransmitter systems
Mecca, A. P. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.04.003 · Cited by 13
Late‐Stage 18F‐Difluoromethyl Labeling of N‐Heteroaromatics with High Molar Activity for PET Imaging
Trump, L., Lemos, A., Lallemand, B., Pasau, P., Mercier, J., Lemaire, C. F., Luxen, A., & Génicot, C. (2019) · Angewandte Chemie · doi:10.1002/ange.201907488 · Cited by 12
Self-citationNaganawa, M., Gallezot, J., Finnema, S. J., Maguire, R. P., Mercier, J., Nabulsi, N., Kervyn, S., Henry, S. E., Nicolas, J.-M., Huang, Y. H., et al. (2022) · EJNMMI Research · doi:10.1186/s13550-022-00944-5 · Cited by 11
Self-citationNavacerrada, M. E. S., Becker, G., Bahri, M. A., Seret, A., Mestdagh, N., Mercier, J., Miévis, F., Giacomelli, F., Lemaire, C. F., Salmon, É., et al. (2019) · Molecules · doi:10.3390/molecules24091705 · Cited by 12
Self-citationImaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET)
Rossano, S. M., Toyonaga, T., Berg, E., Lorence, I., Fowles, K., Nabulsi, N., Ropchan, J. R., Li, S., Ye, Y., Felchner, Z., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05825-6 · Cited by 11
Self-citationMolecular PET Imaging in Alzheimer’s Disease
Thientunyakit, T., Shiratori, S., Ishii, K., & Gelovani, J. G. (2022) · Journal of Medical and Biological Engineering · doi:10.1007/s40846-022-00717-4 · Cited by 12
Erbb4Deletion From Inhibitory Interneurons Causes Psychosis-Relevant Neuroimaging Phenotypes
Kiemes, A., Navacerrada, M. E. S., Kim, E., Randall, K., Simmons, C., Gonzalez, L. R., Petrinovic, M. M., Lythgoe, D. J., Rotaru, D., Censo, D. D., et al. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac192 · Cited by 12
Thompson, S., Kealey, S., Sephton, S. M., & Aigbirhio, F. I. (2020) · doi:10.1002/9781119500575.ch7 · Cited by 11
SV2A-PET imaging uncovers cortical synapse loss in multiple sclerosis
Gavilanes, E. M. U., Bartos, L. M., Gernert, J. A., Carral, C. A., Navarro, D. R., Havla, J. B., Gerdes, L. A., Gnörich, J. S., Kunze, L. H., Dorneich, J. S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adt5585 · Cited by 14
Kong, Y., Zhang, S., Huang, L., Zhang, C., Xie, F., Zhang, Z., Huang, Q., Jiang, D., Li, J., Zhou, W., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.731114 · Cited by 11
Pfeifer, V., Zeltner, T., Fackler, C., Kraemer, A., Thoma, J., Zeller, A., & Kiesling, R. (2021) · Angewandte Chemie · doi:10.1002/ange.202109043 · Cited by 10
Recent advances in photochemistry for positron emission tomography imaging
Zhang, J., Lou, L., Lv, R., Chen, J., Li, Y., Wu, G., Cai, L., Liang, S. H., & Chen, Z. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109342 · Cited by 10
Validation and test–retest repeatability performance of parametric methods for [11C]UCB-J PET
Tuncel, H., Boellaard, R., Coomans, E. M., Hollander-Meeuwsen, M. D., de Vries, E. F. J., Glaudemans, A. W. J. M., Feltes, P. K., García, D. V., Verfaillie, S. C. J., Wolters, E. E., et al. (2022) · EJNMMI Research · doi:10.1186/s13550-021-00874-8 · Cited by 9
Antons, M. J., Lindner, M. J., Grosch, M., Oos, R., Palumbo, G., Brendel, M., Ziegler, S. I., Bartenstein, P., Dieterich, M., & Zwergal, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-09936-w · Cited by 9
Local depletion of large molecule drugs due to target binding in tissue interstitial space
Zasedateleva, T., Schaller, S., de Lange, E. C. M., & de Witte, W. E. A. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13262 · Cited by 9
Imaging Synaptic Density in Aging and Alzheimer Disease with [ 18 F]SynVesT-1
Giorgio, J., Soleimani‐Meigooni, D. N., Janabi, M., Baker, S. L., Chen, X., Toueg, T. N., Weimer, R. M., Zinnhardt, B., Green, A., Rabinovici, G. D., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.269005 · Cited by 12
DiFilippo, A. H., Jonaitis, E. M., Ennis, G. E., McVea, A. K., McLachlan, M., Bettcher, B., Schulz, N., Pasquesi, M., Davenport‐Sis, N. J., Thor, Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70321 · Cited by 10
Schifani, C., Hafizi, S., Silva, T. M. S., Watts, J. J., Khan, M. S., & Mizrahi, R. (2017) · International Review of Psychiatry · doi:10.1080/09540261.2017.1396205 · Cited by 10
O’Dell, R. S., Higgins‐Chen, A., Gupta, D., Chen, M., Naganawa, M., Toyonaga, T., Lu, Y., Ni, G. S., Chupak, A., Zhao, W., et al. (2023) · NeuroImage Clinical · doi:10.1016/j.nicl.2023.103457 · Cited by 9
Self-citationvan Aalst, J., Jennen, L., Demyttenaere, K., Sunaert, S. G., Koole, M. J. B., Ceccarini, J., & Laere, K. V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.739356 · Cited by 10
Sun, C., Revilla, E. M., Zhang, J., Fontaine, K. M., Toyonaga, T., Gallezot, J., Mulnix, T., Onofrey, J. A., Carson, R. E., & Lu, Y. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119678 · Cited by 10
Self-citationWillekens, S. M. A., Weehaeghe, D. V., Damme, P. V., & Laere, K. V. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3587-y · Cited by 9
Salardini, E., O’Dell, R. S., Tchorz, E., Nabulsi, N., Huang, Y. H., Carson, R. E., van Dyck, C. H., & Mecca, A. P. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01739-1 · Cited by 8
Self-citationVogler, L., Ballweg, A., Bohr, B., Briel, N., Wind-Mark, K., Antons, M. J., Kunze, L. H., Gnörich, J. S., Lindner, S., Gildehaus, F., et al. (2023) · NeuroImage Clinical · doi:10.1016/j.nicl.2023.103484 · Cited by 11
The chemistry of labeling heterocycles with carbon-11 or fluorine-18 for biomedical imaging
Lu, S., Siméon, F. G., Telu, S., Cai, L., & Pike, V. W. (2020) · Advances in heterocyclic chemistry · doi:10.1016/bs.aihch.2019.11.005 · Cited by 9
Bærentzen, S. L., Waszkiewicz, A. L., Thomsen, M., Knudsen, C., Elfving, B., & Landau, A. M. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104079 · Cited by 7
Laroy, M., Casteele, T. V., Cauwenberge, M. G. A. V., Koole, M. J. B., Dupont, P. J., Sunaert, S. G., den Stock, J. V., Sienaert, P. A., Laere, K. V., Vandenbulcke, M., et al. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.04.020 · Cited by 10
Husain, M. O., Jones, B., Arshad, U., Ameis, S. H., Mirfallah, G., Schifani, C., Rodak, T., Aiken, M., Shafique, M. S., Ahmed, F., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05788-y · Cited by 9
Fibre density and cross-section associate with hallmark pathology in early Alzheimer’s disease
Vanderlinden, G., Radwan, A., Christiaens, D., Blommaert, J., Sunaert, S. G., Vandenbulcke, M., Koole, M. J. B., & Laere, K. V. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01710-0 · Cited by 7
Synaptic Density in Multiple Sclerosis
Luoma, A., Matilainen, M., Tuisku, J., Aarnio, R., Nikkilä, T., Laaksonen, S., Koivumäki, M., Honkonen, E., Nylund, M., Wahlroos, S., et al. (2025) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200435 · Cited by 8
Chen, B., Zheng, C., Balayeva, T., Toyonaga, T., Wang, X., Tong, J., Mennie, W., Mihailovic, J. M., Coman, D., Hyder, F., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.269291 · Cited by 7
Self-citationMeasurement of synaptic density in Down syndrome using PET imaging: a pilot study
DiFilippo, A. H., Jonaitis, E. M., Makuch, R., Piro‐Gambetti, B., Fleming, V., Ennis, G. E., Barnhart, T. E., Engle, J. W., Bendlin, B. B., Johnson, S. C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-54669-7 · Cited by 7
Synaptic density patterns in early Alzheimer’s disease assessed by independent component analysis
Fang, X. T., Raval, N. R., O’Dell, R. S., Naganawa, M., Mecca, A. P., Chen, M.-K., van Dyck, C. H., & Carson, R. E. (2024) · Brain Communications · doi:10.1093/braincomms/fcae107 · Cited by 7
Self-citationMarkicevic, M., Mandino, F., Toyonaga, T., Cai, Z., Fesharaki‐Zadeh, A., Shen, X., Strittmatter, S. M., & Lake, E. M. R. (2024) · Journal of Neurotrauma · doi:10.1089/neu.2024.0095 · Cited by 8
Mittal, A., Martin, M. F., Provins, L., Hall, A., Ledecq, M., Wolff, C., Gillard, M., Horanyi, P. S., & Coleman, J. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2510239122 · Cited by 7
Pidathala, S., Chen, X., Dai, Y., Nguyen, L. N., Gorgulla, C., Niu, Y., Liu, F., & Lee, C. (2025) · Nature Communications · doi:10.1038/s41467-025-65781-1 · Cited by 7
Myburgh, P. J., & Sai, K. K. S. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00200 · Cited by 6
Binda, K. H., Real, C. C., Simonsen, M. I. T., Grove, E. K., Bender, D., GJEDDE, A. H., Brooks, D. J., & Landau, A. M. (2024) · Psychophysiology · doi:10.1111/psyp.14709 · Cited by 5
Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density
Cawthorne, C., Maguire, R. P., Mercier, J., Sciberras, D. G., Serdons, K., Bormans, G. M., Hoon, J. N. J. M. D., Laere, K. V., & Koole, M. J. B. (2021) · EJNMMI Physics · doi:10.1186/s40658-021-00384-5 · Cited by 6
Self-citationMcErlain, H., McLean, E., Morgan, T. E. F., Burianova, V. K., Tavares, A., & Sutherland, A. J. (2022) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c01895 · Cited by 6
Zheng, C., Toyonaga, T., Chen, B., Nicholson, L., Mennie, W., Liu, M., Spurrier, J. M., DeLuca, K., Strittmatter, S. M., Carson, R. E., et al. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1045644 · Cited by 5
Self-citationKinetic models for estimating occupancy from single-scan PET displacement studies
Laurell, G. L., Plavén‐Sigray, P., Johansen, A., Raval, N. R., Nasser, A., Madsen, C. A., Madsen, J., Hansen, H. D., Donovan, L. L., Knudsen, G. M., et al. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231168591 · Cited by 6
First-in-Human PET Imaging of [ 18 F]SDM-4MP3: A Cautionary Tale
Desmond, K. L., Lindberg, A., García, A., Tong, J., Harkness, M. B., Dobrota, E., Smart, K. A., Uribe, C., Meyer, J. H., Houle, S., et al. (2023) · Molecular Imaging · doi:10.1155/2023/8826977 · Cited by 7
Self-citationPracitto, R., Wilcox, K. C., Lindemann, M., Tong, J., Zheng, C., Li, S., Finnema, S. J., Huang, Y. H., & Cai, Z. (2021) · ACS Omega · doi:10.1021/acsomega.1c02433 · Cited by 6
Self-citationThe pharmacokinetics of [18F]UCB-H revisited in the healthy non-human primate brain
Goutal, S., Guillermier, M., Becker, G., Gaudin, M., Bramoullé, Y., Luxen, A., Lemaire, C. F., Plenevaux, A., Salmon, É., Hantraye, P., et al. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00777-8 · Cited by 7
Sirindil, F., Maher, S., Schöll, M., Sander, K., & Årstad, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415481 · Cited by 5
Overview of Clinically Available Radiotracers for Imaging in Neurodegenerative Disorders
Pike, V. W. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_3 · Cited by 5
Lu, X., Ji, B., Huang, G., & Ding, H. Y. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.04.013 · Cited by 5
Berckmans, L., Schrauwen, C., Miranda, A., Staelens, S. G., & Bertoglio, D. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07170-w · Cited by 6
PET Imaging of Mitochondrial Function in the Living Brain
Tsukada, H. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86492 · Cited by 5
Molecular imaging biomarkers in familial frontotemporal lobar degeneration: Progress and prospects
Wang, R., Gao, H., Xie, H., Jia, Z., & Chen, Q. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.933217 · Cited by 4
Evaluation of advanced, pathophysiologic new targets for imaging of CNS
Singh, P., Singh, D., Srivastava, P., Mishra, G., & Tiwari, A. K. (2023) · Drug Development Research · doi:10.1002/ddr.22040 · Cited by 5
Progress and Challenges in the Development of PET Ligands to Aid CNS Drug Discovery
Mercier, J., Provins, L., & Hannestad, J. O. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12437-0 · Cited by 7
Self-citationIdentification of pre-synaptic density networks using [11C]UCB-J PET imaging and ICA in mice
Akkermans, J., Zajicek, F., Miranda, A., Adhikari, M. H., & Bertoglio, D. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119771 · Cited by 4
Precision medicine in neurosurgery: The evolving role of theranostics
Patel, D., Nguyen, A., Fleeting, C. R., Patel, A. B., Mumtaz, M., & Lucke-Wold, B. P. (2023) · INNOSC Theranostics and Pharmacological Sciences · doi:10.36922/itps.417 · Cited by 5
Asch, R., Naganawa, M., Nabulsi, N., Huan, Y., Esterlis, I., & Carson, R. E. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231200423 · Cited by 5
Self-citation
Metadata
- Authors
- Nabulsi, N. B., Mercier, J., Holden, D., Carré, S., Najafzadeh, S., Vandergeten, M.-C., Lin, S.-F., Deo, A., Price, N., Wood, M., Lara-Jaime, T., Montel, F., Laruelle, M., Carson, R. E., Hannestad, J., & Huang, Y.
- Affiliations
- Yale University (US)
- UCB Pharma (Belgium) (BE)
- Intra Cellular Therapies (United States) (US)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2016-02-04
- Volume
- 57
- Issue
- 5
- Pages
- 777-784
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2311377444
- Cited by
- 296
- References
- 31
- Citations by year
- 2026: 20 · 2025: 27 · 2024: 31 · 2023: 32 · 2022: 58 · 2021: 41 · 2020: 38 · 2019: 25 · 2018: 10 · 2017: 9 · 2016: 5
- FWCI
- 14.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Yale University
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- [11C]UCB-J, SV2A, PET radiotracer, radiotracer synthesis, Suzuki coupling, target occupancy, receptor binding, tissue distribution, rhesus monkeys, antiepileptic drugs
- MeSH terms
- Animals, Brain, Female, Humans, Macaca mulatta, Male, Membrane Glycoproteins, Permeability, Pyridines, Pyrrolidines, Pyrrolidinones, Radiochemistry, Tissue Distribution, Positron-Emission Tomography, Rats, Chemistry Techniques, Synthetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
